CORDIS
EU research results

CORDIS

English EN

Breast Cancer Somatic Genetics Study

Objective

All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million cases diagnosed annually. It is responsible for >400,000 deaths per year making it the leading cause of cancer deaths in women and is the most common cause of all deaths in women aged >40yrs. Breast cancer is a heterogeneous disease with a number of subtypes. We propose here to generate complete catalogues of somatic mutations in 500 breast cancers, of the ER+ve HER2- subclass, under the International Cancer Genome Consortium model by high coverage, shotgun genome sequencing of both tumour and normal DNA. All classes of mutations are expected to be detected including base substitutions, insertions, deletions, copy number changes and rearrangements. These catalogues of mutations will afford us statistical power to identify cancer genes that are mutated at a frequency of greater than 3% in this class of breast cancer. Complementary catalogues of epigenomic changes (genome-wide DNA methylation) will be generated for the same cancer samples together with transcript expression profiles. Integrated analyses of these data will be carried out and compared to parallel datasets from other classes of breast cancer and other types of cancer. The potential clinical utility of these findings for detection and monitoring of minimal residual disease will be investigated. Finally, data will be made rapidly available to all scientific researchers with minimal restrictions. The results of this exhaustive and comprehensive set of studies will have an enormous impact on our understanding of the causes and biology of breast cancer and will lead to major advances in detection, prevention and treatment of breast cancer
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GENOME RESEARCH LIMITED

Address

The Gibbs Building, Euston Road 215
Nw1 2be London

United Kingdom

Activity type

Research Organisations

EU Contribution

€ 6 167 201

Administrative Contact

Martin Dougherty (Dr.)

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

OSLO UNIVERSITETSSYKEHUS HF

Norway

EU Contribution

€ 633 000

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 349 500

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 764 113

CANCER RESEARCH UK LBG

United Kingdom

EU Contribution

€ 116 557

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 471 000

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 746 700

DANA-FARBER CANCER INSTITUTE INC

United States

EU Contribution

€ 220 269

INSTITUT JULES BORDET

Belgium

EU Contribution

€ 45 600

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 90 716

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 264 475

INSTITUT NATIONAL DU CANCER GIP

France

EU Contribution

€ 498 000

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 121 425

Sloan-Kettering Institute for Cancer Research CORPORATION

United States

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 11 443

Project information

Grant agreement ID: 242006

Status

Closed project

  • Start date

    1 July 2010

  • End date

    31 December 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 13 875 833,15

  • EU contribution

    € 10 499 999

Coordinated by:

GENOME RESEARCH LIMITED

United Kingdom

This project is featured in...